You are here: Industry Insights > mAb

News List

Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers. firstwordpharma
July 28, 2021
Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of high quality, monoclonal antibody (mAb) biosimilar therapeutics
COVID-19 antibody therapies safe and effective for transplant patients europeanpharmaceuticalreview
June 16, 2021
Monoclonal antibody therapies found to reduce progression to severe disease, risk of hospitalisation and death in transplant recipients with mild to moderate COVID-19.
Zydus seeks DCGI nod for clinical trials of monoclonal antibodies cocktail to treat COVID-19 infection expresspharma
May 31, 2021
ZRC-3308 is a cocktail of two monoclonal antibodies targeting two unique epitopes on the spike protein of SARS-CoV-2.
Avantor Boosts Global Production of Single Use Technologies contractpharma
May 17, 2021
Avantor Inc., a global provider of products and services to customers in the life sciences, is increasing global capacity for single-use technologies used in the production of biologics and vaccines.
Hybrid purifier removes host cell proteins during mAb bioprocessing, study shows europeanpharmaceuticalreview
November 17, 2020
Researchers have shown that a hybrid purifier can remove host cell proteins during the downstream processing of monoclonal antibodies.
Aduro Biotech Appoints CMO contractpharma
April 23, 2019
Nuyten brings expertise as a radiation oncologist specializing in cancer biology...
Poteligeo approved in Europe for Mycosis Fungoides, Sézary Syndrome pharmatimes
November 27, 2018
Kyowa Hakko Kirin (Kyowa Kirin) has received marketing authorisation Europe for use of Poteligeo to treat Mycosis Fungoides and Sézary Syndrome, the two most common subtypes of cutaneous T-cell lymphoma, a rare type of non-Hodgkin’s lymphoma.
Poteligeo approved in Europe for Mycosis Fungoides, Sézary Syndrome pharmatimes
November 27, 2018
Kyowa Hakko Kirin (Kyowa Kirin) has received marketing authorisation Europe for use of Poteligeo to treat Mycosis Fungoides and Sézary Syndrome, the two most common subtypes of cutaneous T-cell lymphoma, a rare type of non-Hodgkin’s lymphoma.